License Agreement Sample Contracts

Lexaria Corp – License Agreement (January 22nd, 2019)

This License Agreement (the "Agreement"), effective as of January 15, 2019 (the "Effective Date"), is entered into by and among Altria Client Services LLC, a Virginia limited liability company with offices located at 6601 West Broad Street, Richmond, Virginia 23220 ("Licensee"), Lexaria Nicotine LLC, a Delaware limited liability company with a principal office and place of business at 100-740 McCurdy Road, Kelowna, BC V1X 2P7, Canada ("Licensor"), and Lexaria Bioscience Corp., a Nevada corporation with a principal office and place of business at 100-740 McCurdy Road, Kelowna, BC V1X 2P7, Canada ("Trademark Licensor"). Licensor and Trademark Licensor may be referred to herein collectively as the "Licensor Parties," and Licensee, Licensor, and Trademark Licensor may be referred to herein individually as a "Party" or collectively as the "Parties."

Avedro Inc – License Agreement (January 18th, 2019)
Patent and Know-How License Agreement (January 18th, 2019)
Patent and Know-How License Agreement (January 18th, 2019)
Level Brands, Inc. – Mutual Termination of License Agreement (January 11th, 2019)

This Mutual Termination of License Agreement (this "Termination") is made and entered into on January 7, 2019 (the "Execution Date"), by and between Level Brands, Inc., a North Carolina corporation ("Licensor"), and Isodiol International Inc., a Canadian corporation ("Licensee"). Licensor and Licensee may be referred to herein each as a "Party" or collectively as the "Parties".

AquaMed Technologies, Inc. – License Agreement (January 9th, 2019)

This License Agreement (this "Agreement"), dated as of April 13, 2017 (the "Effective Date"), is by and between Tikun Olam Ltd., an Israeli corporation, registration number 514263771 ("Licensor") and Tikun Olam IP Ltd., a Cayman Islands company ("Licensee"). Licensor and Licensee shall each be individually referred to as a "Party" and collectively as the "Parties".

AquaMed Technologies, Inc. – License Agreement (January 9th, 2019)

This License Agreement (this "Agreement"), dated as of April 13, 2017 (the "Effective Date"), is by and between Tikun Olam Ltd., an Israeli corporation, registration number 514263771 ("Licensor") and TO Pharmaceuticals USA LLC, a Delaware limited liability company ("Licensee"). Licensor and Licensee shall each be individually referred to as a "Party" and collectively as the "Parties".

Poseida Therapeutics, Inc. – License Agreement (January 4th, 2019)
Poseida Therapeutics, Inc. – License Agreement (January 4th, 2019)
Super League Gaming, Inc. – License Agreement (January 4th, 2019)
Super League Gaming, Inc. – Dan D. Nabel Riot Games, Inc. 12333 W. Olympic Blvd. Los Angeles, CA 90064 dnabel@riotgames.com November 21, 2017 VIA EMAIL & FEDERAL EXPRESS Super League Gaming, Inc. 2912 Colorado Ave., Suite 200 Santa Monica, CA 90404 Attn: General Counsel gregg@superleague.com Re: Extension of License Agreement Dear Gregg: (January 4th, 2019)

I am writing about the license agreement (the "Agreement") made as of June 22, 2016 between Riot Games, Inc. ("Riot") and Super League Gaming, Inc. ("SLG"). Although SLG has not achieved its KPIs as defined in Section 6.2, Riot hereby elects to extend the Agreement for the Extension Term pursuant to Section 6.3.

Athenex, Inc. – LICENSE AGREEMENT by and Between ATHENEX, INC. And CHONGQING TAIHAO PHARMACEUTICAL CO LTD December 30, 2018 (January 3rd, 2019)
Lightlake Therapeutics Inc. – LICENSE AGREEMENT Between SANOFI and OPIANT PHARMACEUTICALS, INC. Dated as of December 21, 2018 (December 28th, 2018)

This License Agreement (this "Agreement") is made and entered into as of December 21, 2018 (the "Effective Date") by and between Sanofi, a French corporation ("Sanofi" or "Licensor") and Opiant Pharmaceuticals, Inc., a Delaware corporation, having offices located at 201 Santa Monica Blvd., Suite 500, Santa Monica, California, USA 90401 ("Opiant"). Sanofi and Opiant are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Tcr2 Therapeutics Inc. – [***] Indicates Material That Has Been Omitted and for Which Confidential Treatment Has Been Requested. All Such Omitted Material Has Been Filed With the Securities and Exchange Commission Pursuant to Rule 406 Promulgated Under the Securities Act of 1933, as Amended License Agreement (December 28th, 2018)
Harpoon Therapeutics, Inc. – Chef1 Collaboration & License Agreement (December 27th, 2018)
Avedro Inc – License Agreement (December 21st, 2018)
Adial Pharmaceuticals, L.L.C. – Amendment #6 to License Agreement (December 19th, 2018)

This Amendment #6, dated as of December 18, 2018 (this "Agreement"), to the License Agreement (as defined below) is by and between the University of Virginia Patent Foundation d/b/a the University of Virginia Licensing and Ventures Group, a Virginia not-for-profit corporation of the Commonwealth of Virginia, having its principal offices at 1180 Seminole Tr., Suite 495, Charlottesville, VA 29901 ("UVA LVG"), and Adial Pharmaceuticals, Inc, a Delaware corporation (f/k/a ADial Pharmaceuticals, LLC) ("Adial" and together with "UVA LVG", the "Parties").

Proteostasis Therapeutics, Inc. – Proteostasis Therapeutics Announces Global License Agreement With Genentech Agreement Covers Small Molecule Modulators of the Cellular Proteostasis Network (December 17th, 2018)
Harpoon Therapeutics, Inc. – Chef1 Collaboration & License Agreement (December 12th, 2018)
OptiNose, Inc. – Optinose Announces Update to License Agreement With Avanir Pharmaceuticals for ONZETRA XSAIL (December 11th, 2018)

YARDLEY, Pa., Dec. 11, 2018-- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company received written notice from Avanir Pharmaceuticals, Inc. of its election to terminate the License Agreement to develop and commercialize ONZETRA(r) XSAIL(r) in the United States, Canada, and Mexico. As a result, the License Agreement is expected to terminate on March 10, 2019.

Avedro Inc – License Agreement (November 19th, 2018)
Biohaven Pharmaceutical Holding Co Ltd. – License Agreement (November 14th, 2018)

This License Agreement (the "Agreement") is made and entered into effective as of September 04, 2018 (the "Effective Date") by and between AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 Sodertalje, Sweden and with offices at SE-431 83 Molndal, Sweden ("AstraZeneca") and Biohaven Therapeutics Ltd. British Virgin Business Corporation with offices at 215 Church Street, Haven, CT 06510 ("Licensee"). AstraZeneca and Licensee are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Synthorx, Inc. – License Agreement (November 13th, 2018)
Corbus Pharmaceuticals Holdings, Inc. – License Agreement (November 8th, 2018)

THIS LICENSE AGREEMENT (the "Agreement") is made effective as of September 20th, 2018 (the "Effective Date") by and between Corbus Pharmaceuticals, Inc., a Delaware corporation having a place of business at 500 River Ridge Drive, Second Floor, Norwood, MA 02062 ("Corbus") and Jenrin Discovery, LLC, a Delaware limited liability company having a place of business at 285 Wilmington-West Chester Pike, Chadds Ford, PA 19317 ("Jenrin").

Hpil Holding – Dated 30th October, 2018 LICENSE AGREEMENT (November 6th, 2018)
Global Blood Therapeutics, Inc. – License Agreement (November 6th, 2018)
VistaGen Therapeutics, Inc. – License Agreement (October 30th, 2018)

This License Agreement ("Agreement"), effective on October 24, 2018, is by and between Pherin Pharmaceuticals, Inc., a California corporation with offices at 1014 Barbara Avenue, Mountain View, CA 94040 ("LICENSOR"), and VistaGen Therapeutics, Inc., a Nevada corporation with offices at 343 Allerton Avenue, South San Francisco, California 94080 ("LICENSEE").

VistaGen Therapeutics, Inc. – License Agreement (October 29th, 2018)

This License Agreement ("Agreement"), effective on October 24, 2018, is by and between Pherin Pharmaceuticals, Inc., a California corporation with offices at 1014 Barbara Avenue, Mountain View, CA 94040 ("LICENSOR"), and VistaGen Therapeutics, Inc., a Nevada corporation with offices at 343 Allerton Avenue, South San Francisco, California 94080 ("LICENSEE").

Harpoon Therapeutics, Inc. – License Agreement (October 24th, 2018)
Elite Pharmaceuticals, Inc. – MANUFACTURING AND LICENSE AGREEMENT Between Elite Pharmaceuticals, Inc. And Epic Pharma LLC MANUFACTURING AND LICENSE AGREEMENT (October 17th, 2018)

This License Agreement ("Agreement") is entered into as of the 1st day of October, 2013 by and between EPIC PHARMA LLC, a Delaware limited liability company ("EPIC"), and ELITE PHARMACEUTICALS, INC., a Nevada corporation and ELITE LABORATORIES, INC. (a subsidiary of Elite Pharmaceuticals, Inc.), a Delaware corporation (collectively, "ELITE").

Gossamer Bio, Inc. – License Agreement (October 11th, 2018)
Axonics Modulation Technologies, Inc. – October 1, 2013 Axonics Modulation Technologies, Inc. 16411 Scientific Way Suite 200 Irvine, CA 92618 Dear Sirs: Reference Is Made to That Certain License Agreement of Even Date Herewith Between Axonics Modulation Technologies, Inc. And the Undersigned. This Will Confirm That at Your Option the Undersigned Will Expand the Territories Included Under the License to Be Worldwide Or, if You So Direct, the Undersigned Will Enter Into a Comparable License Agreement Covering Areas Outside the United States With an Entity Controlled by the Founders of Axonics Modulation Technologies, Inc. In the Latte (October 5th, 2018)
Axonics Modulation Technologies, Inc. – License Agreement (October 5th, 2018)
Tpt Global Tech, Inc. – PRODUCT, SOFTWARE & SERVICES LICENSE AGREEMENT Between New Orbit Technologies, S.A.P.I. De C.V. And TPT Global Tech, Inc. Dated April 17, 2017 (October 2nd, 2018)
StoneCo Ltd. – Contrato De Participacao Nos Arranjos De Pagamento Da Visa Do Brasil E Licenciamento De Marca Registrada Visa Payment Arrangements Participation and Trademark Blicense Agreement (October 1st, 2018)